All Oncology News

Efrat Dotan, MD, discusses routine provider assessment vs the utility of geriatric assessment in geriatric patients with gastroesophageal disease.

The FDA granted an orphan drug designation to ocifisertib for use as a potential therapeutic option in patients with acute myeloid leukemia.

David A. Sallman, MD, discusses the potential use of fedratinib to manage symptomatic myelodysplastic syndrome/myeloproliferative neoplasms.

The S1706 study is currently enrolling patients with inflammatory breast cancer to determine if adding a PARP inhibitor to radiation therapy is effective.

Jonathan Constance, PhD, and his team have created a digital pharmacology platform for assessing drug dynamics directly among children with cancer.

A biologics license application for linvoseltamab in relapsed/refractory multiple myeloma has been accepted for priority review by the FDA.

Tatyana Feldman, MD, highlights updated data for liso-cel in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

IMM-1-104 received FDA fast track designation for use in patients with pancreatic ductal adenocarcinoma who have progressed on 1 line of treatment.

The FDA has approved a supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) at a reduced dose of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma who have achieved and maintained a complete response or greater for at least 6 months.

Vorasidenib has been granted regulatory submission acceptance by the FDA and EMA for IDH-mutant diffuse glioma.

Burton Eliot Appel, MD, discusses the importance of recognizing Childhood Cancer Day in pediatric patients with cancer.

Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.

New technique made human T cells 100 times more potent at killing cancer cells.

A sNDA for adagrasib plus cetuximab in advanced KRAS G12C–mutated colorectal cancer was granted priority review by the FDA.

The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA.

Lurbinectedin demonstrated greater activity and a superior safety profile vs topotecan in a subset of small cell lung cancer.

Neoadjuvant tislelizumab plus platinum-based doublet chemotherapy followed by surgery and adjuvant tislelizumab demonstrated efficacy in resectable non–small cell lung cancer.

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

Catherine J. Wu, MD, of Dana-Farber Cancer Institute, has been awarded the Sjöberg Prize today for her pioneering research in the field of personalized vaccines to treat cancer.

The European Medicines Agency has granted orphan drug designation to UV1 in patients with mesothelioma.

A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.

Jane L. Meisel, MD, discusses the importance of prioritizing patients’ toxicity concerns and quality of life in the management of breast cancer.

Jobelle Baldonado, MD, highlights the emergence of targeted therapies and the need for reflex-ordered molecular testing in early-stage lung cancer.

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Carrie L. Kitko, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.

The FDA has approved osimertinib (Tagrisso) plus chemotherapy for use in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

The FDA has approved lifileucel suspension (Amtagvi) for adult patients with unresectable or metastatic melanoma following prior treatment with a PD-1 inhibitor, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor.

The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.